<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31530">Edaravone</z:chebi> is a novel free radical scavenger that is clinically employed in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, its effect on <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced subventricular zone (SVZ) neurogenesis is largely unknown </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigated the effect and underlying mechanism of <z:chebi fb="0" ids="31530">edaravone</z:chebi> administration on SVZ neurogenesis using a rat model of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>-reperfusion injury </plain></SENT>
<SENT sid="3" pm="."><plain>Male Sprague-Dawley rats (200-250 g) were divided into sham operated (n=15), control (n=50), and <z:chebi fb="0" ids="31530">edaravone</z:chebi>-treated (n=50) groups </plain></SENT>
<SENT sid="4" pm="."><plain>Rats in the control and <z:chebi fb="0" ids="31530">edaravone</z:chebi>-treated groups underwent 90 min of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) following reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Immediately and 12 h after MCAO, the rats received either <z:mpath ids='MPATH_458'>normal</z:mpath> saline (control group) or <z:chebi fb="0" ids="31530">edaravone</z:chebi> (<z:chebi fb="0" ids="31530">edaravone</z:chebi>-treated group) intraperitoneally </plain></SENT>
<SENT sid="6" pm="."><plain>5-<z:chebi fb="1" ids="22927,47265">bromo</z:chebi>-2-deoxyuridine (BrdU) was used to label proliferating cells </plain></SENT>
<SENT sid="7" pm="."><plain>Six, 12, and 24 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, reactive oxygen species (ROS) generation, <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor 1α (HIF-1α), and vascular endothelial growth factor (VEGF) protein levels in ischemic ipsilateral SVZ were determined </plain></SENT>
<SENT sid="8" pm="."><plain>Immunohistochemistry staining for BrdU and doublecortin (DCX) was performed at 1, 4, and 7 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with <z:chebi fb="0" ids="31530">edaravone</z:chebi> not only mitigated cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> size (P&lt;0.05) and neurological defects (P&lt;0.05), but also <z:mp ids='MP_0000352'>decreased cell proliferation</z:mp> and neural progenitor cells in the ischemic ipsilateral SVZ (P&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>Additionally, <z:chebi fb="0" ids="31530">edaravone</z:chebi> reduced effectively ROS generation and HIF-1α as well as VEGF protein levels in the ischemic ipsilateral SVZ (P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>These findings indicate that administration with <z:chebi fb="0" ids="31530">edaravone</z:chebi>, via repressing HIF-1α signaling pathway, inhibits SVZ neurogenesis in rats after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>-reperfusion injury </plain></SENT>
</text></document>